Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06485271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 3, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment
Trial Details
NCT Number NCT06485271
Lead Sponsor Changzhi People's Hospital Affiliated to Changzhi Medical College
Conditions
(from sponsor)		 Gastric Cancer, RWS, PD-1 Immunotherapy
Related terms Stomach Neoplasms
Enrollment 504 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov